Chemoradiotherapy interactions and lung toxicity

Annals of Oncology

Volumn 10, Issue SUPPL. 5, 1999, Pages

  Trott, K R ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Drug radiation interactions; Lung damage; Non small cell lung cancer; Radiochemotherapy

Indexed keywords

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONFERENCE PAPER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; PRIORITY JOURNAL; RADIATION DOSE;

EID: 0032718460     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_5.S77     Document Type: Conference Paper

References (14)

1. Stewart LA for the Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-909.
2. Troll KR. Exploitable radiobiological mechanisms in radio-chemotherapy. In Kogelnik HD, Sedlmayer F (eds): Progress in Radiation Oncology VI. Bologna: Monduzzi Editore 1998: 311-6.
3. Saunders MI, Dische S, Barrett A et al. Continuous, hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer. A randomized multicentre trial. Lancet 1997; 350: 161-5.
4. Dische S, Saunders MI, Barrett A et al. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997; 44: 123-36.
5. Saunders MI. CHART: The results and the relevance to clinical practice. In Kogelnik HD, Sedlmayer F (eds): Progress in Radiation Oncology VI. Bologna: Monduzzi Editore 1998; 753-66.
6. Withers HR, Suwinski R. Treatment of subclinical metastases. In Kogelnik HD, Sedlmayer F (eds): Progress in Radiation Oncology VI. Bologna: Monduzzi Editore 1998; 187-9.
7. Baumann M, Herrmann T, Matthiesen W et al. CHARTWEL-bronchus (ARO-97-1). Eine randomisierte multizentrische Studie zum Vergleich einer konventionell fraktionierten Strahlentherapie mit CHARTWEL-Bestrahlung bei inoperablen nichtkleinzelligen Bronchialkarzinomen. Strahlenther Onkolog 1997; 173: 663-7.
8. Saunders MI, Rojas A, Lyn BE et al. The experience with a dose escalation study using CHARTWEL in non-small-cell lung cancer. Br J Cancer 1997.
9. Peters LJ, Ang K, Thames HD. Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Acta Oncol 1988; 27: 185-95.
10. Rubin P, Johnston C, Williams J. Perpetual cascade of cytokines post-radiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 1994; 304-12.
11. Rubin P. Late effects of chemotherapy and radiation therapy: A new hypothesis. Int J Radiat Oncol Biol Phys 1984; 10: 5-34.
12. van der Maase H, Overgaard J, Vaeth M. Effect of cancer chemotherapeutic drugs on radiation-induced lung damage in mice. Radiother Oncol 1986; 5; 245-57.
13. Kelly K, Hazuka M, Pan Z et al. A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 1998; 40: 559-67.
14. Bourhis J, Pignon JP, Domenge C et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC) locoregional treatment versus same treatment plus chemotherapy. In Kogelnik HD, Sedlmayer F (eds): Progress in Radiation Oncology VI. Bologna: Monduzzi Edilore 1998; 793-5.